BioSig Tech. (BSGM) & Electrophysiology Sector - Looks like MDT just might need better renal ablation / renal-denervation signals despite working on - BioSig Tech. (BSGM) & Electrophysiology Sector - InvestorVillage


BioSig Tech. (BSGM) & Electrophysiology Sector (related stock BSGM)
This is a semi-private group. You are free to browse messages, but you must be a member of this group to post messages. Join This Group

Group: BioSig Tech. (BSGM) & Electrophysiology Sector   /  Message Board  /  Read Message

 
 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  2231 of 2252  at  10/18/2021 6:43:02 PM  by

Rob Cos

The following message was updated on 10/18/2021 7:32:10 PM.

Looks like MDT just might need better renal ablation / renal-denervation signals despite working on for a decade

  
 
With peer review now published and the glorious HRS feedback BSGM should finally be able to sell to hospitals besides the two world class anchor users The Mayo Clinic amd TCAI.  They also should be able to partner PURE EP IP with multiple companies and then renal ablation my guess H122 with Medtronic.   Seems like MDT still needs better signals in renal ablation despite a decade working on it on their own…..
 
 Medtronic Stock Is Sliding Because Its Hypertension Treatment Trial Didn't End Early -- Barrons.com

2021-10-18 17:44:41.119 GMT

By Joe Woelfel

(Dow Jones) -- Medtronic was falling Monday after the medical device maker
said a clinical study of its renal-denervation system wasn't stopped early as
expected by analysts who thought the outcome would be more positive.

The stock was down 5.2% to $121.10.

Medtronic (ticker: MDT) said late Friday in a regulatory filing that a
clinical trial of its Symplicity renal-denervation system, a device to treat
hypertension, would continue until completed. The company said that would be
sometime in the second half of next year, while analysts had expected the
trial to be stopped early.

"The company is announcing ... that it has received notification from its ON
MED study independent data safety monitoring board that it has conducted the
prespecified interim data analysis and has recommended that clinical trial
enrollment continue as planned, until the full, predefined sample size is
reached," Medtronic said in an 8-K filing.

Medtronic said it expects renal denervation to "become a multi-billion dollar
market." The company said it expects global market revenue to now exceed $500
million by 2026 and $2 billion to $3 billion by 2030.

The company said Friday that its update wouldn't affect its fiscal 2022
guidance on earnings and revenue. In August, Medtronic said in its quarterly
earnings report that expected adjusted earnings in 2022 of $5.65 to $5.75 a
share, higher than previous guidance of between $5.60 and $5.75.

Analysts at SVB Leerink said it anticipated results from the ON MED study to
be positive but noted that ultimately an approval is expected in 2023.

"The RDN dream is by no means over," the analysts said. SVB Leerink rates the
stock at Market Perform.

Analysts at Cowen said they "misjudged" Medtronic's transparency about the
study's interim analysis as a "strong sign that the trial would be stopped
early for statistical success. We believe others did as well, and thus we
expect the stock to face pressure on Monday."

The study can, however, still have positive results and "the 12-month delay
for RDN's U.S. launch doesn't alter our model significantly."

Cowen reiterated its Outperform rating on the stock and its $141 price target.

Analysts surveyed by FactSet have an average weighting on the stock of Buy
with a price target of $146.75.
 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 7  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
2232 Re: Looks like MDT just might need better renal ablation / renal-denervation signals despite working on for a decade gpg39 6 10/19/2021 11:17:09 AM


Financial Market Data provided by
.
Loading...